DUBLIN--(BUSINESS WIRE)--The "Chronic Fatigue Syndrome Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering.
Global chronic fatigue syndrome therapeutics market report looks at factors such as increasing use of off-label pharmacological treatment for CFS, increasing risk factors of CFS, and initiatives to increase awareness about CFS. However, lack of specific diagnostic tests for confirmation of CFS, lack of approved drugs for the treatment of CFS, and complex pathogenesis of CFS may hamper the growth of the chronic fatigue syndrome therapeutics industry over the forecast period.
The chronic fatigue syndrome (CGS) therapeutics market analysis considers sales from pain relievers and NSAIDs, antidepressant and antipsychotic drugs, and antimicrobial and immunomodulatory drugs. In 2018, the pain relievers and NSAIDs segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as relieving patients from pain and reducing inflammation will play a significant role in the pain relievers and NSAIDs segment to maintain its market position.
Global Chronic Fatigue Syndrome Therapeutics Market: Overview
Increasing risk factors of CFS
Some theories indicate that viral infection, psychological stress, genetic factors increase the risk of CFS. The prevalence of CFS is four times more in women than in men. Chronic physical or emotional stress also may result in CFS. Stress affects the hypothalamic-pituitary-adrenal axis, which is a complex network that controls the body's reaction, such as immune response, digestion, energy usage, and mood. The prevalence of stress is increasing globally due to many societal factors and work-related pressure which is increasing the risk factors of CFS. These risk factors of CFS will lead to the expansion of the global chronic fatigue syndrome therapeutics market at a CAGR of over 4% during the forecast period.
R&D of new drugs for the treatment of CFS
The lack of approved and effective drugs has led the vendors to focus on the R&D of novel drugs to cater to the unmet need in CFS pharmacological therapy. Researchers at Stanford University School of Medicine are harnessing the nanoelectronics-based diagnostic test, developed by them, to screen for drug-based treatments. These treatments are screened by adding controlled doses of several different potentially therapeutic drugs to the patient's blood samples and performing diagnostic tests. The research funding for CFS has increased over the last couple of years. This development is expected to have a positive impact on the overall market growth.
With the presence of several major players, the global chronic fatigue syndrome therapeutics market is moderately fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic fatigue syndrome therapeutics manufacturers, that include Hemispherx Biopharma Inc., Lupin Ltd., Mylan NV, Pfizer Inc., Teva Pharmaceutical Industries Ltd.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Pain relievers and NSAIDs - Market size and forecast 2018-2023
- Antidepressant and antipsychotic drugs - Market size and forecast 2018-2023
- Antimicrobial and immunomodulatory drugs - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
- Development of new diagnostic tests for CFS
- R&D of new drugs for the treatment of CFS
- Increasing focus on investigation
- Role of immune system in CFS
PART 12: VENDOR LANDSCAPE
- Landscape disruption
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Hemispherx Biopharma, Inc.
- Lupin Ltd.
- Mylan NV
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/uqo32o